Top > Search of International Patents > BIOMARKER FOR DIAGNOSING MUSCLE DISEASE

BIOMARKER FOR DIAGNOSING MUSCLE DISEASE

Foreign code F200010080
File No. 5876
Posted date May 15, 2020
Country WIPO
International application number 2018JP043998
International publication number WO 2019111797
Date of international filing Nov 29, 2018
Date of international publication Jun 13, 2019
Priority data
  • P2017-233758 (Dec 5, 2017) JP
Title BIOMARKER FOR DIAGNOSING MUSCLE DISEASE
Abstract The present invention aims to provide a biomarker for early diagnosis of muscle disease. In addition, the present invention aims to provide a measurement technology that facilitates early diagnosis of muscle disease using said biomarker. The biomarker for muscle disease and comprising anti-DDB1 antibodies is useful as a biomarker for early diagnosis of muscle disease. A muscle disease detection method including a step in which anti-DDB1 antibodies in a blood sample derived from a test subject are detected is useful for the early detection of muscle disease. Ideally said muscle disease is polymyositis.
Outline of related art and contending technology BACKGROUND ART
Inflammatory disease muscle (Inflammatory Myopathy; IM) is, as well as muscle, skin, as well as, lung, heart, including organs such as joints and systemic autoimmune disease. IM is, the Bohan and Peter 1975 years has been proposed (Non-Patent Document 1) the diagnostic criteria based on the classified polymyositis and dermatomyositis is included.
Generally myositis diagnosis, symptoms and clinical findings including muscle, and the inspection findings (specifically, the blood test (creatine kinase value, aldolase value of the myogenic enzyme values), physiological examination (needle and electromyogram), the image inspection (MRI), histological examination (muscle biopsy) ) is performed by. In a definitive diagnosis of the particular IM, muscle biopsy is an important role.
Recently, many myositis-specific antibody (myositis-specific autoantibodies; MSA) and myositis-associated autoantibodies (myositis-associated autoantibodies; MAA) has been reported. These MSA and the MAA, closely related to the clinical features are notable. So far, and the MSA in the sera of patients when MAA is detected, diagnostic of a disease, predicting the clinical course, in the early stages of disease and treatment determination is facilitated. Such autoantibodies, muscle weakness or abnormal laboratory finding easier identification of the cause of the symptoms and the like, or a muscle biopsy or the like of the early MRI aggressive the inspection criteria for determining the useful points.
On the other hand, damage to the DNA binding protein 1(DNA damage-binding protein 1; DDB1) DNA repair protein involved in the processes is found as. DDB1 Is, the relevance of the ultraviolet light (non-patent document 3 and 4), and the relevance of the virus infection is also reported (Non-Patent Document 5-11) respectively.
Scope of claims (In Japanese)[請求項1]
 抗DDB1抗体からなる、筋疾患のバイオマーカー。

[請求項2]
 前記筋疾患が多発性筋炎である、請求項1に記載のバイオマーカー。

[請求項3]
 被験対象に由来する血液試料中の抗DDB1抗体の検出を行う工程を含む、筋疾患の検出方法。

[請求項4]
 前記血液試料が血清である、請求項3に記載の検出方法。

[請求項5]
 前記被験対象の臨床所見が、皮膚症状を実質的に呈さない、請求項3又は4に記載の検出方法。

[請求項6]
 前記筋疾患が多発性筋炎である、請求項3~5のいずれかに記載の検出方法。

[請求項7]
 前記被験対象の血液検査所見が、筋原性酵素について正常値である、請求項3~6のいずれかに記載の検出方法。

[請求項8]
 前記被験対象の血液検査所見が、クレアチンキナーゼ300U/L以上である、請求項3~6のいずれかに記載の検出方法。

[請求項9]
 前記被験対象の血液検査所見が、アルドラーゼ6.2IU/L以上である、請求項3~6及び8のいずれかに記載の検出方法。

[請求項10]
 前記検出を、DDB1タンパク質又はその部分ペプチドからなる抗原を用いて行う、請求項3~9のいずれかに記載の検出方法。

[請求項11]
 前記検出をELISA法によって行う、請求項10に記載の検出方法。

[請求項12]
 DDB1タンパク質又はその部分ペプチドからなる抗原を含む、筋疾患の検査用試薬。

[請求項13]
 請求項12に記載の検査用試薬を含む、筋疾患の診断キット。
  • Applicant
  • ※All designated countries except for US in the data before July 2012
  • KYOTO UNIVERSITY
  • Inventor
  • HOSONO, Yuji
  • MIMORI, Tsuneyo
  • SASAI, Ran
IPC(International Patent Classification)
Specified countries National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DJ DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JO JP KE KG KH KN KP KR KW KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
Please contact us by e-mail or facsimile if you have any interests on this patent. Thanks.

PAGE TOP

close
close
close
close
close
close